<p>Innovent Biologics and Daiichi Sankyo have entered an exclusive agreement under which Daiichi Sankyo will handle development, manufacturing and supply of Vanflyta while Innovent holds sole commercialization rights and will lead market promotion in China. The company claims Vanflyta was approved in C</p>